Turner Syndrome Market Size, Share & Industry Analysis, By Type (Growth Hormone Therapy, Estrogen Replacement Therapy, Progestogen Add-on Therapy, and Others), By Age Group (Adult and Pediatric), By Route of Administration (Oral, Parenteral, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

The global Turner syndrome market size was valued at USD 604.1 million in 2024. The market is projected to grow from USD 642.7 million in 2025 to USD 991.9 million by 2032, exhibiting a CAGR of 6.40% during the forecast period.

The Turner syndrome market is estimated to witness noteworthy growth during the forecast period. It is a rare chromosomal disorder that affects only females due to a characterized partial or complete absence of one X chromosome. Thus, to promote height and physical development and management of puberty and reproductive health, hormonal therapy is given to females. Furthermore, to address such conditions in the diagnosed population, hormonal therapies are required. Moreover, the market’s growth will also be supported by the launch of off-label generic drugs.

For instance, in June 2025, as per the data published by NIH, Turner syndrome occurs in approximately 1 in 2000 to 1 in 2500 live female births worldwide.

The market encompasses several major players with Novo Nordisk A/S, and Pfizer Inc. at the forefront with robust portfolio and strategic activities to support their dominance.

MARKET DYNAMICS

MARKET DRIVERS

Increasing Prevalence and Awareness Programs to Propel Market Growth

One of the most prominent driving factors of the market is the increasing number of cases of Turner syndrome in females. Also, rising awareness campaigns and newborn screening programs are being implemented to improve diagnosis and enhance treatment adoption.

• For instance, Turner’s Syndrome Society of the U.S. organizes a Turner syndrome awareness campaign in February of every year, with an aim to increase self-awareness and early diagnosis of Turner syndrome and health care for the community.

MARKET RESTRAINTS

High Cost of Therapy and Limited Reimbursement in Emerging Countries to Restrict Market Growth

The high cost of hormonal therapy for growth treatment is one of the major factors hampering its adoption in the lower-income countries. The high cost is associated with limited patient pool for clinical studies and investments by key players for such diseases.
Also, many patients in these regions face financial challenges due to limited healthcare infrastructure and insurance coverage,.

As per the Turner Syndrome Foundation, growth treatment costs around USD 10,000 to USD 60,000 a year in the U.S. 

MARKET OPPORTUNITIES

Development of Long-Acting Growth Hormone Formulations to Create Lucrative Growth Opportunities

Traditional growth hormone therapy requires daily subcutaneous injections. This can be painful, uncomfortable, and increase the burden on patients, which can and hamper their lifestyle. Thus, to enhance treatment adherence and patient convenience, key players are focused on developing and launching extended-release therapies. This will reduce injection frequency and improve quality of life and compliance.

• In June 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved NGENLA, a human growth hormone analog for once-weekly administration for the treatment of pediatric patients with growth failure.

MARKET CHALLENGES

Lack of Treatment Adherence May Challenge Market Growth

Poor treatment adherence among patients due to lack of awareness, forgetfulness, side effects, or psychological barriers is challenging the Turner syndrome market growth. Moreover, many patients discontinue therapies, thus reducing treatment effectiveness.

TURNER SYNDROME MARKET TRENDS

Increasing Research and Development Activities Support Market Growth

The rising focus of key players to develop and launch advanced treatment options for Turner’s syndrome is a major market trend. Rising prevalence of Turner syndrome lead to increasing demand for innovative product offerings. Moreover, heightened focus on R&D result in improved patient outcomes and address unmet medical needs.

• In December 2024, Ascendis Pharma A/S announced positive topline results from New InsiGHTS, a Phase 2 randomized, open-label, active-controlled study to evaluate the safety, tolerability, and effectiveness of once-weekly TransCon hGH (lonapegsomatropin) in comparison to daily somatropin in prepubertal children with Turner syndrome.

Download Free sample to learn more about this report.

Segmentation Analysis

By Type 

Increasing Government Schemes for Growth Hormone Therapy to Propel Segment Growth

On the basis of type, the market is classified into growth hormone therapy, estrogen replacement therapy, progestogen add-on therapy, and others.

To know how our report can help streamline your business, Speak to Analyst

The growth hormone therapy segment held a dominant Turner syndrome market share in 2024 due to its effectiveness in promoting growth and physical development in the affected individuals. Also, it is a first-line treatment for Turner's syndrome. Furthermore, increasing approvals and government programs to offer growth hormone treatment to patients is boosting the segment’s growth.

• For instance, in February 2025, the Health Ministry of Kerala, India, launched growth hormone (GH) treatment under the State’s KARE (Kerala United Against Rare Diseases) scheme.

The estrogen replacement therapy segment is expected to grow at a CAGR of 6.92% over the forecast period.

By Age Group

New Product Launches for Adults to Bolster the Segment’s Growth

In terms of age group, the market is categorized into adult and pediatric.

The adult segment dominates the market with an anticipated 61.0% share in 2025. The increasing demand for estrogen–progestogen therapy in adults, after adolescence growth hormone therapy, is contributing toward its growth.

• For instance, in July 2025, Ascendis Pharma A/S announced the approval of SKYTROFA for replacing endogenous growth hormone in adults with growth hormone deficiency (GHD).

The pediatric segment is expected to grow at a CAGR of 5.38% over the forecast period.

By Route of Administration

Wide Availability and Approvals Boost Parenteral Segment Growth

Based on route of administration, the market is segmented into oral, parenteral, and others.

The parenteral segment held the dominating position in 2024 and will sustain its dominance by accounting for a 68.1% market share in 2025. The dominant share of the segment is due to the better bioavailability and efficacy of the parenteral route. Also, growth hormone therapy is one of the prominent treatments, and it is primarily administered through subcutaneous or intramuscular injections. 

• In January 2022, Pfizer Inc. announced the approval of NGENLA (somatrogon) Inj. 24 mg Pens and 60 mg Pens by the Ministry of Health, Labour and Welfare (MHLW) in Japan.

The oral segment is set to flourish with a growth rate of 7.57% over the forecast period. 

By Distribution Channel

Patient Preference and Ease of Availability to Propel Drug Store and Retail Pharmacies

Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies & drug stores, and online pharmacies.

In 2024, the retail pharmacies & drug stores segment dominated and in 2025 is set to hold 50.0% market share. These channels have widespread accessibility and allow easy refilling of prescriptions for the patients and caregivers.

In addition, hospital pharmacies as a distribution channel are projected to grow at a CAGR of 5.58% during the study period. The increasing government recommendation for growth hormone treatment in children is to boost the distribution of these drugs via hospital pharmacy channels.

• For instance, in June 2025, the National Institute for Health and Care Excellence (NICE), U.K., recommended Sogroya for children aged 3 to 17 years with growth hormone deficiency.

Turner Syndrome Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa. 

North America

North America held a dominant share in 2024 with a market size of USD 227.9 million, and will lead in 2025 with an estimated USD 239.5 million. Its dominance is driven by advanced healthcare infrastructure, reimbursement coverage, and awareness programs. In 2025, the U.S. market is estimated to reach USD 226.7 million. 

The U.S. is expected to dominate North America’s market, owing to the rising cases of Turner syndrome and the presence of adequate reimbursement policies for better patient care. Additionally, the presence of key players in the market with strong research and development initiatives boosts the country’s growth.

To get more information on the regional analysis of this market, Download Free sample

• In July 2023, the U.S.FDA approved Opill (norgestrel) tablet, a progestin therapy also used in Turner syndrome treatment in adults.

Europe & Asia Pacific

Europe and the Asia Pacific, are anticipated to witness a notable growth in the coming years. During the forecast period, Europe is projected to record the second-highest growth rate of 5.30% and touch USD 192.7 million in 2025. The increasing Turner syndrome awareness programs and government initiatives for adequate treatment primarily drive this. Backed by these factors, the U.K. is expected to record USD 30.6 million, followed by Germany at USD 39.8 million and France at USD 34.0 million in 2025. Meanwhile, Asia Pacific is estimated to reach USD 167.0 million in 2025 and secure the position of the third-largest region in the market. In 2025, India and China are estimated to reach USD 26.7 and USD 40.9 million respectively. 

Latin America and the Middle East & Africa

Over the forecast period, Latin America and the Middle East & Africa regions will witness moderate growth. In 2025, Latin America’s market size will reach USD 30.4 million fueled by increasing diagnosis and early treatment. In the Middle East & Africa, GCC is set to attain USD 6.3 million in 2025. 

COMPETITIVE LANDSCAPE

Key Industry Players

Market Participants Focus on Expansion of Product Offering and Strong R&D Activities to Maintain Their Position

The global Turner syndrome market shows a fragmented structure with large-sized companies actively operating. These players have a robust product portfolio with strong research and development abilities.

Pfizer Inc., Novo Nordisk A/S, and Ferring Pharmaceuticals are some of the dominating players in the market due to their strong range of products with strategic activities to launch new products.

Apart from this, Bayer AG, Takeda Pharmaceutical Company Limited, and Sandoz, among others are major key players. These players are focusing on offering various products for the treatment of Turner syndrome to enhance their market presence.

LIST OF KEY TURNER SYNDROME COMPANIES PROFILED

• Novo Nordisk A/S (Denmark)
• Pfizer Inc. (U.S.)
• Sandoz (Switzerland)
• Ferring Pharmaceuticals (Switzerland)
• Merck Co. & Inc. (Germany)
• Ascendis Pharma A/S (Denmark)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bayer AG (Germany)

KEY INDUSTRY DEVELOPMENTS

• October 2025: Novo Nordisk A/S announced the commercialization of Sogroya (somapacitan injection) in Canada.
• May 2025: BioMarin Pharmaceutical Inc. announced results for VOXZOGO (vosoritide), for the treatment of achondroplasia as well as Turner syndrome in children.
• December 2023: Ascendis Pharma A/S announced positive results from the Phase 3 trials to compare TransCon hGH (lonapegsomatropin) with placebo and daily hGH (human growth hormone, somatropin) in adults with Growth Hormone Deficiency (GHD).
• February 2022: Pfizer Inc. and OPKO Health, Inc. announced that the European Commission granted marketing authorization for NGENLA (somatrogon), a once-weekly injection to treat children and adolescents with pediatric growth hormone deficiency.
• April 2020: Ascendis Pharma A/S (Nasdaq: ASND) announced that the U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to TransCon hGH (lonapegsomatropin) for the treatment of Growth Hormone Deficiency (GHD).

REPORT COVERAGE 

The global Turner syndrome market analysis provides an in-depth study of the market size & forecast by all segments included in the report. It includes details on market dynamics, market trends, and market opportunities. The report also offers information on new product launches, key industry developments, and details on partnerships, mergers & acquisitions, as well as regulatory and reimbursement guidelines at the global level. It encompasses a detailed pipeline analysis and competitive landscape with information on the market share and profiles of key operating players.

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation